<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1137-6627</journal-id>
<journal-title><![CDATA[Anales del Sistema Sanitario de Navarra]]></journal-title>
<abbrev-journal-title><![CDATA[Anales Sis San Navarra]]></abbrev-journal-title>
<issn>1137-6627</issn>
<publisher>
<publisher-name><![CDATA[Gobierno de Navarra. Departamento de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1137-66272023000300010</article-id>
<article-id pub-id-type="doi">10.23938/assn.1055</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Manejo de glomerulonefritis membranoproliferativa secundaria a infección por virus de hepatitis C]]></article-title>
<article-title xml:lang="en"><![CDATA[Management of membranoproliferative glomerulonephritis secondary to infection by hepatitis C virus]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lasierra-Lavilla]]></surname>
<given-names><![CDATA[Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Perona-Caro]]></surname>
<given-names><![CDATA[Amalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[del Agua-Arias-Camisón]]></surname>
<given-names><![CDATA[Celia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caballero-Castro]]></surname>
<given-names><![CDATA[Julien Paola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Servicio Aragonés de Salud Hospital Obispo Polanco Servicio de Medicina Interna]]></institution>
<addr-line><![CDATA[Teruel ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Servicio Aragonés de Salud Hospital Obispo Polanco Servicio de Nefrología]]></institution>
<addr-line><![CDATA[Teruel ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Servicio Aragonés de Salud Clínico Universitario Lozano Blesa Servicio de Anatomía Patológica]]></institution>
<addr-line><![CDATA[Zaragoza ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>46</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1137-66272023000300010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1137-66272023000300010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1137-66272023000300010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Las glomerulonefritis membranoproliferativas son nefropatías glomerulares poco frecuentes cuya prevalencia ha disminuido en nuestro medio. Presentan una histología característica y pueden asociarse a diferentes enfermedades. La presentación clínica es variada y su diagnóstico definitivo requiere realizar una biopsia renal. El tratamiento viene condicionado por la enfermedad de base, tratándose con inmunosupresores cuando existe una disminución del filtrado glomerular. Presentamos el caso de una mujer de 47 años con glomerulonefritis membranoproliferativa secundaria a infección por de virus de hepatitis C para describir el manejo de este tipo de pacientes, dado que se trata de una patología con una baja prevalencia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Membranoproliferative glomerulonephritis is an uncommon condition that affects the glomeruli of the kidneys; its prevalence has decreased in our environment. Membranoproliferative glomerulonephritis has a characteristic histology that can be associated to different diseases. The clinical presentation varies, and to achieve a definitive diagnosis a renal biopsy must be done. Treatment is based on the underlying disease; when a drop in glomerular filtration rate is detected, immunosuppressants are prescribed. We describe the management of a 47-year-old female with membranoproliferative glomerulonephritis secondary to hepatitis C virus infection, a condition with very low prevalence.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Glomerulonefritis membranoproleferativa]]></kwd>
<kwd lng="es"><![CDATA[Virus de la Hepatitis C]]></kwd>
<kwd lng="es"><![CDATA[Antivirales]]></kwd>
<kwd lng="es"><![CDATA[Corticoesteroides]]></kwd>
<kwd lng="es"><![CDATA[Eritrocitos anormales]]></kwd>
<kwd lng="en"><![CDATA[Membranoproliferative glomerulonephritis]]></kwd>
<kwd lng="en"><![CDATA[Hepatitis C virus]]></kwd>
<kwd lng="en"><![CDATA[Glecaprevir-Pibrentasvir]]></kwd>
<kwd lng="en"><![CDATA[Corticoids]]></kwd>
<kwd lng="en"><![CDATA[Abnormal erythrocytes]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sethi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fervenza]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Membranoproliferative glomerulonephritis - a new look at an old entity]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>366</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1119-31</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group</collab>
<article-title xml:lang=""><![CDATA[KDIGO 2021 Clinical practice guideline for the management of glomerular diseases]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2021</year>
<volume>100</volume>
<numero>4S</numero>
<issue>4S</issue>
<page-range>S1-S276</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masani]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Jhaveri]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Fishbane]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update on membranoproliferative GN]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2014</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>600-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chae]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New classification of membranoproliferative glomerulonephritis: a good start but a long way to go]]></article-title>
<source><![CDATA[Kidney Res Clin Pract]]></source>
<year>2014</year>
<volume>33</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>171-3</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdelhamid]]></surname>
<given-names><![CDATA[WAR]]></given-names>
</name>
<name>
<surname><![CDATA[Shendi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zahran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Elbary]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Fadda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatitis C-related membranoproliferative glomerulonephritis in the era of direct antiviral agents]]></article-title>
<source><![CDATA[J Bras Nefro]]></source>
<year>2022</year>
<volume>44</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>291-5</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<collab>Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group</collab>
<article-title xml:lang=""><![CDATA[KDIGO 2022 Clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2022</year>
<volume>102</volume>
<numero>6S</numero>
<issue>6S</issue>
<page-range>S129-205</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masai]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wakui]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Komatsuda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Togashi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Maki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ohtani]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics of proliferative glomerulo-nephritis with monoclonal IgG deposits associated with membranoproliferative features]]></article-title>
<source><![CDATA[Clin Nephrol]]></source>
<year>2009</year>
<volume>72</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46-54</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sethi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zand]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[RJH]]></given-names>
</name>
<name>
<surname><![CDATA[Jevremonic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Herrmann]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2010</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>770-82</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roccatello]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Baldovino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mansouri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Naretto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gennaro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2004</year>
<volume>19</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3054-61</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Favà]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cruzado]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Pascual]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soler]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment for hepatitis C virus-associated mixed cryoglobulinaemia]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2018</year>
<volume>7</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
